Okay, let's tackle this question about the CD marker of MALT lymphoma. First, I need to recall what MALT lymphoma is. MALT stands for Mucosa-Associated Lymphoid Tissue lymphoma, which is a type of non-Hodgkin lymphoma. It's usually low-grade and often associated with chronic inflammation, like in the stomach (gastric MALToma) due to H. pylori infection.

The question is asking for the CD marker. CD markers are cluster of differentiation molecules used to identify cell types. For MALT lymphoma, I remember that it's a B-cell lymphoma, so the markers should be B-cell specific. The key CD markers for B-cells are CD19, CD20, and CD22. But there's also CD5 which is more associated with T-cells or certain B-cell lymphomas like chronic lymphocytic leukemia.

Wait, MALT lymphoma is typically CD5 negative. So if an option includes CD5, that's a distractor. Also, CD4 and CD8 are T-cell markers, so those are out. CD3 is another T-cell marker. CD23 is found in some B-cell lymphomas but I think it's more associated with mantle cell lymphoma or others.

The correct marker for MALT lymphoma is CD20. That's a key point because CD20 is a B-cell marker and used in treatment with rituximab. So the correct answer should be CD20. Now, the options given here are missing, but based on common MCQs, the correct answer is CD20. Let me check if there's any other possible marker. CD19 is also B-cell, but CD20 is more specific for B-cell lymphomas.

So, the core concept is that MALT lymphoma is a B-cell lymphoma, and CD20 is the key marker. The clinical pearl is that CD20 is targeted by rituximab. The wrong options would be CD5, CD4/CD8 (T-cell), or others like CD30 or CD34 which aren't relevant here. The explanation should clarify why CD20 is correct and why the others are not.

**Core Concept**
MALT lymphoma (Mucosa-Associated Lymphoid Tissue lymphoma) is a B-cell non-Hodgkin lymphoma characterized by the expression of **CD20**. It commonly arises in extranodal sites like the stomach, often linked to chronic antigenic stimulation (e.g., *H. pylori* infection).

**Why the Correct Answer is Right**
CD20 is a surface antigen present on mature B-cells and their neoplasms, including MALT lymphoma. It is critical for B-cell activation and signaling. Monoclonal antibodies like **rituximab** target CD20, making it a diagnostic and therapeutic marker. MALT lymphoma typically lacks CD5 (T-cell marker), CD3 (T-cell marker), and CD4/CD8 (T-cell lineage markers), distinguishing it from other lymphomas.

**Why Each Wrong Option is Incorrect**
**Option A:** CD5 is expressed in T-cell lymphomas (e.g., T-cell CLL/SLL) and some B-cell lymphomas (e.g., mantle

✓ Correct Answer: C. CD 20